BioStock: CEO of Lipum looks ahead to 2024

Throughout 2023, Lipum's primary focus has been on the clinical phase I study with SOL-116. A mid-year capital raise empowered the company to further accelerate and a CEO transition was announced in the latter part of the year. Ola Sandborgh is now assuming the helm for the company's next developmental phase, and BioStock reached out to delve into the plans for 2024.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/12/ceo-of-lipum-looks-ahead-to-2024/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se